Novavax, Inc. (NVAX)

Novavax, Inc. (NVAX) is a healthcare company (biotechnology) based in the United States. The share price is $7.98, down 1.05% on the day, which values the company at $1.32B. Price as of 17 Nov 2026, 20:53 UTC, from Yahoo Finance.

Key facts

Share price
$7.98−1.05% today
Market value
$1.32B
Funk Score
55/100
200-week average
$8.385% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Novavax, Inc. in more detail

NVAX trades at -44.3× next year's expected earnings, 3.2× sales. It sits 5% below its 200-week average of $8.38.

Over the last five fiscal years Novavax, Inc. has compounded revenue 18.8% a year. Its Funk Score is 55 out of 100 (financial strength 7.1, profitability 5.3, growth 5.8, value 3.8, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Beneish M-score flags the accounts.

1 of the superinvestors tracked here hold NVAX, including Philippe Laffont (0.1% of the portfolio).

Superinvestors holding NVAX

1 of the investors tracked here report a position in their latest 13F filing.

Novavax, Inc. (NVAX): questions and answers

What is NVAX's PEG ratio?

Novavax, Inc.'s PEG ratio is 1.32 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Novavax, Inc.'s market cap?

Novavax, Inc. is valued at $1.32B at a share price of $7.98.

Is NVAX above its 200-week moving average?

No. NVAX is 4.8% below its 200-week average of $8.38. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Novavax, Inc. growing?

Over the last five fiscal years Novavax, Inc.'s revenue grew 18.8% a year; over ten years revenue grew 41.0% a year.

Does NVAX pay a dividend?

Novavax, Inc. does not currently pay a regular dividend.

Which famous investors own NVAX?

In their latest quarterly filings, Philippe Laffont (0.1% of the portfolio) hold NVAX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Novavax, Inc. (NVAX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NVAX

Underlying data: Yahoo Finance; company filings with the SEC.